Form 4: Denali Therapeutics Director Vicki L Sato Sells 1,020 Shares

Director Vicki L Sato of Denali Therapeutics Inc. sold 1,020 shares of common stock at $30 per share on September 13, 2024, according to a Form 4 filing.

Summary

• On September 13, 2024, Vicki L Sato, a director of Denali Therapeutics Inc., sold 1,020 shares of common stock.
• The sale was executed at a price of $30 per share.
• Following the transaction, Sato directly owns 115,156 shares of Denali Therapeutics Inc., which includes 5,967 unvested RSUs.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by a director under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine disclosure of a stock sale by a company insider. Such transactions are common and can be driven by various personal financial planning reasons. It's important to consider the context of insider transactions within the broader performance and outlook of the company.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder confidence, but the effect is likely to be minimal given the relatively small number of shares sold and the existence of a pre-arranged trading plan.

Key Dates